Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 266

1.

Hypomethylation of noncoding DNA regions and overexpression of the long noncoding RNA, AFAP1-AS1, in Barrett's esophagus and esophageal adenocarcinoma.

Wu W, Bhagat TD, Yang X, Song JH, Cheng Y, Agarwal R, Abraham JM, Ibrahim S, Bartenstein M, Hussain Z, Suzuki M, Yu Y, Chen W, Eng C, Greally J, Verma A, Meltzer SJ.

Gastroenterology. 2013 May;144(5):956-966.e4. doi: 10.1053/j.gastro.2013.01.019. Epub 2013 Jan 16.

2.

Alterations of the Wnt signaling pathway during the neoplastic progression of Barrett's esophagus.

Clément G, Braunschweig R, Pasquier N, Bosman FT, Benhattar J.

Oncogene. 2006 May 18;25(21):3084-92.

PMID:
16407829
3.

Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.

Jin Z, Hamilton JP, Yang J, Mori Y, Olaru A, Sato F, Ito T, Kan T, Cheng Y, Paun B, David S, Beer DG, Agarwal R, Abraham JM, Meltzer SJ.

Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):111-7. doi: 10.1158/1055-9965.EPI-07-0407.

4.

Temporal evolution in caveolin 1 methylation levels during human esophageal carcinogenesis.

Jin Z, Wang L, Cao Z, Cheng Y, Gao Y, Feng X, Chen S, Yu H, Wu W, Zhao Z, Dong M, Zhang X, Liu J, Fan X, Mori Y, Meltzer SJ.

BMC Cancer. 2014 May 20;14:345. doi: 10.1186/1471-2407-14-345.

5.

Cellular origins and molecular mechanisms of Barrett's esophagus and esophageal adenocarcinoma.

Fang Y, Chen X, Bajpai M, Verma A, Das KM, Souza RF, Garman KS, Donohoe CL, O'Farrell NJ, Reynolds JV, Dvorak K.

Ann N Y Acad Sci. 2013 Oct;1300:187-99. doi: 10.1111/nyas.12249. Review.

PMID:
24117642
6.

Aberrantly methylated PKP1 in the progression of Barrett's esophagus to esophageal adenocarcinoma.

Kaz AM, Luo Y, Dzieciatkowski S, Chak A, Willis JE, Upton MP, Leidner RS, Grady WM.

Genes Chromosomes Cancer. 2012 Apr;51(4):384-93. doi: 10.1002/gcc.21923. Epub 2011 Dec 14.

7.

Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma.

Eads CA, Lord RV, Kurumboor SK, Wickramasinghe K, Skinner ML, Long TI, Peters JH, DeMeester TR, Danenberg KD, Danenberg PV, Laird PW, Skinner KA.

Cancer Res. 2000 Sep 15;60(18):5021-6.

8.

Genome-wide methylation analysis shows similar patterns in Barrett's esophagus and esophageal adenocarcinoma.

Xu E, Gu J, Hawk ET, Wang KK, Lai M, Huang M, Ajani J, Wu X.

Carcinogenesis. 2013 Dec;34(12):2750-6. doi: 10.1093/carcin/bgt286. Epub 2013 Aug 29. Erratum in: Carcinogenesis. 2014 Mar;35(3):738.

9.

Epigenetic alteration of the Wnt inhibitory factor-1 promoter occurs early in the carcinogenesis of Barrett's esophagus.

Clément G, Guilleret I, He B, Yagui-Beltrán A, Lin YC, You L, Xu Z, Shi Y, Okamoto J, Benhattar J, Jablons D.

Cancer Sci. 2008 Jan;99(1):46-53. Epub 2007 Nov 13.

10.

Gene expression profiling reveals stromal genes expressed in common between Barrett's esophagus and adenocarcinoma.

Hao Y, Triadafilopoulos G, Sahbaie P, Young HS, Omary MB, Lowe AW.

Gastroenterology. 2006 Sep;131(3):925-33.

11.

Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.

Zou H, Molina JR, Harrington JJ, Osborn NK, Klatt KK, Romero Y, Burgart LJ, Ahlquist DA.

Int J Cancer. 2005 Sep 10;116(4):584-91.

12.

Activation of GATA binding protein 6 (GATA6) sustains oncogenic lineage-survival in esophageal adenocarcinoma.

Lin L, Bass AJ, Lockwood WW, Wang Z, Silvers AL, Thomas DG, Chang AC, Lin J, Orringer MB, Li W, Glover TW, Giordano TJ, Lam WL, Meyerson M, Beer DG.

Proc Natl Acad Sci U S A. 2012 Mar 13;109(11):4251-6. doi: 10.1073/pnas.1011989109. Epub 2012 Feb 28.

13.
14.

Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk.

Schulmann K, Sterian A, Berki A, Yin J, Sato F, Xu Y, Olaru A, Wang S, Mori Y, Deacu E, Hamilton J, Kan T, Krasna MJ, Beer DG, Pepe MS, Abraham JM, Feng Z, Schmiegel W, Greenwald BD, Meltzer SJ.

Oncogene. 2005 Jun 9;24(25):4138-48.

PMID:
15824739
15.

Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma.

Smith E, De Young NJ, Pavey SJ, Hayward NK, Nancarrow DJ, Whiteman DC, Smithers BM, Ruszkiewicz AR, Clouston AD, Gotley DC, Devitt PG, Jamieson GG, Drew PA.

Mol Cancer. 2008 Oct 2;7:75. doi: 10.1186/1476-4598-7-75.

16.

Whole genome expression array profiling highlights differences in mucosal defense genes in Barrett's esophagus and esophageal adenocarcinoma.

Nancarrow DJ, Clouston AD, Smithers BM, Gotley DC, Drew PA, Watson DI, Tyagi S, Hayward NK, Whiteman DC; Australian Cancer Study; Study of Digestive Health.

PLoS One. 2011;6(7):e22513. doi: 10.1371/journal.pone.0022513. Epub 2011 Jul 28.

17.

Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma.

Agarwal A, Polineni R, Hussein Z, Vigoda I, Bhagat TD, Bhattacharyya S, Maitra A, Verma A.

Int J Clin Exp Pathol. 2012;5(5):382-96. Epub 2012 May 23. Review.

18.

Chromosomal abnormalities and novel disease-related regions in progression from Barrett's esophagus to esophageal adenocarcinoma.

Akagi T, Ito T, Kato M, Jin Z, Cheng Y, Kan T, Yamamoto G, Olaru A, Kawamata N, Boult J, Soukiasian HJ, Miller CW, Ogawa S, Meltzer SJ, Koeffler HP.

Int J Cancer. 2009 Nov 15;125(10):2349-59. doi: 10.1002/ijc.24620.

19.

DNA methylation profiling in Barrett's esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses.

Kaz AM, Wong CJ, Luo Y, Virgin JB, Washington MK, Willis JE, Leidner RS, Chak A, Grady WM.

Epigenetics. 2011 Dec;6(12):1403-12. doi: 10.4161/epi.6.12.18199.

20.

Long Noncoding RNAs in the Pathogenesis of Barrett's Esophagus and Esophageal Carcinoma.

Abraham JM, Meltzer SJ.

Gastroenterology. 2017 Jul;153(1):27-34. doi: 10.1053/j.gastro.2017.04.046. Epub 2017 May 18. Review.

PMID:
28528706

Supplemental Content

Support Center